|
WO2021076856A1
|
|
Muscle targeting complexes and uses thereof for treating myotonic dystrophy
|
|
WO2020247738A1
|
|
Methods of preparing protein-oligonucleotide complexes
|
|
WO2020028844A1
|
|
Muscle targeting complexes and uses thereof for treating centronuclear myopathy
|
|
AU2019316103A1
|
|
Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
|
|
CA3108287A1
|
|
Muscle targeting complexes and uses thereof for treating myotonic dystrophy
|
|
CA3108313A1
|
|
Muscle-targeting complexes and uses thereof in treating muscle atrophy
|
|
WO2020028842A1
|
|
Muscle targeting complexes and uses thereof for treating hypertrophic cardiomyopathy
|
|
WO2020028857A1
|
|
Muscle-targeting complexes and uses thereof
|
|
WO2020028840A1
|
|
Muscle targeting complexes and uses thereof for treating friedreich's ataxia
|
|
WO2020028831A1
|
|
Muscle targeting complexes and uses thereof for treating fibrodysplasia ossificans progressiva
|
|
CA3108285A1
|
|
Muscle targeting complexes and uses thereof for treating pompe disease
|
|
SG11202100934PA
|
|
Muscle targeting complexes and uses thereof for treating dystrophinopathies
|
